Kafelaku Coffee (01869) plans to issue a maximum of 282 million shares for subscription at a discount of approximately 16.5%, raising a net amount of approximately 20.9 million Hong Kong dollars.
Cat poop coffee holdings (01869) announced that on June 16, 2026, the company entered into a placing agreement with the placing agent. According to this agreement, the company has conditionally agreed to place a maximum of 282 million shares at a placing price of HK$0.076 per share to not less than six placees on a best efforts basis through the placing agent. These placees are independent third-party individuals, corporations, institutional investors or other professional investors unrelated to the company and its related parties. The placing shares will be allotted and issued under the general mandate.
KAFELAKU COFFEE (01869) announced that on June 16, 2026, the company entered into a placing agreement with a placing agent. Under this agreement, the company has conditionally agreed to place up to 2.82 billion shares at a placing price of HK$0.076 per share to a minimum of six placees. These placees are third-party individuals, corporations, institutional investors, or other professional investors independent of the company and its associates. The shares will be issued and distributed under the general mandate.
Assuming no changes in the company's issued share capital from the announcement date to the completion of the placing, the maximum of 2.82 billion placing shares represents approximately (i) 20.0% of the company's issued share capital as of the announcement date; and (ii) approximately 16.7% after the full issue and distribution of the placing shares.
The placing price of HK$0.076 per share represents a discount of approximately (i) 16.5% to the closing price of HK$0.091 per share reported on the Stock Exchange on the date of the placing agreement; and (ii) 19.7% to the average closing price of HK$0.0946 per share reported on the Stock Exchange in the five consecutive trading days prior to the placing agreement.
If all placing shares are fully placed, the estimated total proceeds and net proceeds (after deducting placing commissions, other related expenses, and professional fees) from the placing are expected to be HK$21.4 million and approximately HK$20.9 million, respectively.
The company intends to use the net proceeds from the placing for (i) improving the company's financial position by reducing debt and (ii) the business operations and general working capital of the group.
Related Articles

REMEGEN (09995): Wang Weidong re-elected as Chairman of the Board of Directors.

LYUE PHARMA (02186) innovative drug LY03015 (VMAT2 inhibitor/Sigma-1R agonist) has achieved positive results in the Phase II clinical trial for the treatment of delayed onset movement disorders in China.

US Stock Market Move | Qualcomm (QCOM.US) opens up more than 4%, rumored to be in talks to acquire Tenstorrent.
REMEGEN (09995): Wang Weidong re-elected as Chairman of the Board of Directors.

LYUE PHARMA (02186) innovative drug LY03015 (VMAT2 inhibitor/Sigma-1R agonist) has achieved positive results in the Phase II clinical trial for the treatment of delayed onset movement disorders in China.

US Stock Market Move | Qualcomm (QCOM.US) opens up more than 4%, rumored to be in talks to acquire Tenstorrent.

RECOMMEND





